Top

Published in:

Open Access 01-12-2014 | Research

Risk factors of radiation-induced acute esophagitis in non-small cell lung cancer patients treated with concomitant chemoradiotherapy

Authors: ZiCheng Zhang, Jin Xu, Tao Zhou, Yan Yi, HongSheng Li, HongFu Sun, Wei Huang, DongQing Wang, BaoSheng Li, GuoGuang Ying

Published in: Radiation Oncology | Issue 1/2014

Abstract

Background

To analyze the clinical and dosimetric risk factors of acute esophagitis (AE) in non-small-cell lung cancer (NSCLC) patients treated with concomitant chemoradiotherapy.

Methods

Seventy-six NSCLC patients treated with concomitant chemoradiotherapy were retrospectively analyzed. Forty-one patients received concomitant chemoradiotherapy with vinorelbine/cisplatin (VC), 35 with docetaxel/cisplatin (DC). AE was graded according to criteria of the Radiation Therapy Oncology Group (RTOG). The following clinical and dosimetric parameters were analyzed: gender, age, clinical stage, Karnofsky performance status (KPS), pretreatment weight loss, concomitant chemotherapy agents (CCA) (VC vs. DC), percentage of esophagus volume treated to ≥20 (V20), ≥30 (V30), ≥40 (V40), ≥50 (V50) and ≥60 Gy (V60), and the maximum (Dmax) and mean doses (Dmean) delivered to esophagus. Univariate and multivariate logistic regression analysis were used to test the association between the different factors and AE.

Results

Seventy patients developed AE (Grade 1, 19 patients; Grade 2, 36 patients; and Grade 3, 15 patients). By multivariate logistic regression analysis, V40 was the only statistically significant factor associated with Grade ≥2 AE (p<0.001, OR = 1.159). A V40 of <23% had a 33.3% (10/30) risk of Grade ≥2 AE, which increased to 89.1% (41/46) with a V40 of ≥23% (p<0.001). CCA (p =0.01; OR = 9.686) and V50 (p<0.001; OR = 1.122) were most significantly correlated with grade 3 AE. A V50 of <26.5% had a 6.7% (3/45) risk of Grade 3 AE, which increased to 38.7% (12/31) with a V50 of ≥26.5% (p = 0.001). On the linear regression analysis, V50 and CCA were significant independent factors affecting AE duration. Patients who received concomitant chemotherapy with VC had a decreased risk of grade 3 AE and shorter duration compared with DC.

Conclusions

Concomitant chemotherapy agents have potential influence on AE. Concomitant chemotherapy with VC led to lower risk of AE compared with that using DC. V40 and V50 of esophagus can predict grade ≥2 and ≥3 AE, respectively.

Available only for authorised users

Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013, 63: 11-30. 10.3322/caac.21166CrossRefPubMed

Youlden DR, Cramb SM, Baade PD: The International Epidemiology of Lung Cancer: geographical distribution and secular trends. J Thorac Oncol 2008, 3: 819-831. 10.1097/JTO.0b013e31818020ebCrossRefPubMed

Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L, International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions: The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumors. J Thor Oncol 2007, 2: 706-714. 10.1097/JTO.0b013e31812f3c1aCrossRef

Robinson LA, Ruckdeschel JC, Wagner H Jr, Stevens CW, American College of Chest Physicians: Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007,132(Suppl 3):243S-265S.CrossRefPubMed

Socinski MA, Zhang C, Herndon JE 2nd, Dillman RO, Clamon G, Vokes E, Akerley W, Crawford J, Perry MC, Seagren SL, Green MR: Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity. Ann Oncol 2004, 15: 1033-1041. 10.1093/annonc/mdh282CrossRefPubMed

Cox JD, Stetz J, Pajak TF: Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 1995, 31: 1341-1346. 10.1016/0360-3016(95)00060-CCrossRefPubMed

Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC, Uitterhoeve A, Wang X, Stewart L, Arriagada R, Burdett S, Pignon JP: Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010, 28: 2181-2190. 10.1200/JCO.2009.26.2543CrossRefPubMed

Vokes EE, Herndon JE 2nd, Crawford J, Leopold KA, Perry MC, Miller AA, Green MR: Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIb non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 2002, 20: 4191-4198. 10.1200/JCO.2002.03.054CrossRefPubMed

Squier CA, Kremer MJ: Biology of oral mucosa and esophagus. J Natl Cancer Inst Monogr 2001, 29: 7-15.CrossRefPubMed

10.

Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein EB, Mucositis Study Section of the Multinational Association for Supportive Care in Cancer; International Society for Oral Oncology: Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004,100(Suppl 9):1995-2025.CrossRefPubMed

11.

Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, Elting LS, Fox PC, Cooksley C, Sonis ST, Mucositis Study Section of the Multinational Association for Supportive Care in Cancer; International Society for Oral Oncology: Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004,100(Suppl 9):2026-2046.CrossRefPubMed

12.

Peterson DE, Bensadoun RJ, Roila F, ESMO Guidelines Working Group: Management of oral and gastrointestinal mucositis: ESMO clinical practice guidelines. Ann Oncol 2011,22(Suppl 6):vi78-vi84.PubMedCentralPubMed

13.

Jones JA, Avritscher EB, Cooksley CD, Michelet M, Bekele BN, Elting LS: Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer 2006, 14: 505-515. 10.1007/s00520-006-0055-4CrossRefPubMed

14.

Keefe DM, Gibson RJ, Hauer-Jensen M: Gastrointestinal mucositis. Semin Oncol Nurs 2004, 20: 38-47. 10.1053/j.soncn.2003.10.007CrossRefPubMed

15.

Chen YM, Perng RP, Shih JF, Tsai CM, Whang-Peng J: A randomized phase II study of docetaxel or vinorelbine in combination with cisplatin against inoperable, chemo-naïve non-small-cell lung cancer in Taiwan. Lung Cancer 2007, 56: 363-369. 10.1016/j.lungcan.2007.01.011CrossRefPubMed

16.

Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP: Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003, 21: 3016-3024. 10.1200/JCO.2003.12.046CrossRefPubMed

17.

Werner-Wasik M, Yorke E, Deasy J, Nam J, Marks LB: Radiation dose-volume effects in the esophagus. Int J adiat Oncol Biol Phys 2010,76(Suppl 3):S86-S93.CrossRef

18.

Kwint M, Uyterlinde W, Nijkamp J, Chen C, de Bois J, Sonke JJ, van den Heuvel M, Knegjens J, van Herk M, Belderbos J: Acute esophagus toxicity in lung cancer patients after intensity modulated radiation therapy and concurrent chemotherapy. Int J Radiat Oncol Biol Phys 2012,84(2):e223-e228. 10.1016/j.ijrobp.2012.03.027CrossRefPubMed

19.

Algara M, Rodríguez N, Viñals P, Lacruz M, Foro P, Reig A, Quera J, Lozano J, Fernández-Velilla E, Membrive I, Dengra J, Sanz X: Prevention of radiochemotherapy-induced esophagitis with glutamine: results of a pilot study. Int J Radiat Oncol Biol Phys 2007, 69: 342-349. 10.1016/j.ijrobp.2007.03.041CrossRefPubMed

20.

Rodríguez N, Algara M, Foro P, Lacruz M, Reig A, Membrive I, Lozano J, López JL, Quera J, Fernández-Velilla E, Sanz X: Predictors of acute esophagitis in lung cancer patients treated with concurrent three-dimensional conformal radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys 2009, 73: 810-817. 10.1016/j.ijrobp.2008.04.064CrossRefPubMed

Title: Risk factors of radiation-induced acute esophagitis in non-small cell lung cancer patients treated with concomitant chemoradiotherapy
Authors: ZiCheng Zhang
Jin Xu
Tao Zhou
Yan Yi
HongSheng Li
HongFu Sun
Wei Huang
DongQing Wang
BaoSheng Li
GuoGuang Ying
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Radiation Oncology / Issue 1/2014
Electronic ISSN: 1748-717X
DOI: https://doi.org/10.1186/1748-717X-9-54

At a glance: The STEP trials

Springer Medicine

Risk factors of radiation-induced acute esophagitis in non-small cell lung cancer patients treated with concomitant chemoradiotherapy

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

Changes in volume of stage I non-small-cell lung cancer during stereotactic body radiotherapy

A dosimetric comparison of volumetric modulated arc therapy (VMAT) and non-coplanar intensity modulated radiotherapy (IMRT) for nasal cavity and paranasal sinus cancer

mARC vs. IMRT radiotherapy of the prostate with flat and flattening-filter-free beam energies

Dosimetric advantages of a “butterfly” technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin’s lymphoma

Breast conserving treatment for breast cancer: dosimetric comparison of different non-invasive techniques for additional boost delivery

Stereotactic radiosurgery (SRS) for brain metastases: a systematic review